Estimating the Lifetime Clinical Risk/Benefits of Apixaban Versus Edoxaban in Non-Valvular Atrial Fibrillation
Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.762
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2015
Authors
Publisher
Elsevier BV